Form 4: Acrivon Therapeutics Director Acquires RSUs

Michael John Tomsicek, a Director at Acrivon Therapeutics, Inc., acquired 9,366 restricted stock units (RSUs) on May 18, 2026.

Summary

• Michael John Tomsicek, a Director at Acrivon Therapeutics, Inc. (ACRV), acquired 9,366 restricted stock units (RSUs) on May 18, 2026.
• These RSUs represent a contingent right to receive one share of the Issuer's Common Stock per unit.
• The RSUs are scheduled to vest in full on May 18, 2027, provided the Reporting Person remains in continuous service until that date.
• The acquisition was made at a price of $0, indicating it was likely a grant or award rather than a purchase.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it indicates a director's commitment and potential belief in the company's future, but it is a standard equity award rather than a significant new investment.

Positives

• Director acquisition of equity signals confidence in the company's future prospects.
• The grant of RSUs can align management's interests with those of shareholders.
• The acquisition is a non-cash transaction, not immediately impacting the company's cash reserves.

Negatives

• The RSUs are subject to vesting conditions, meaning the director does not yet have full ownership.
• The value of the RSUs is tied to the future performance of Acrivon Therapeutics' stock price.

Risks

• The vesting of RSUs is contingent on the Reporting Person's continuous service, implying a risk of forfeiture if service is terminated before May 18, 2027.
• The value of the acquired securities is subject to market volatility and the company's future performance.

Future Outlook

The future outlook for the acquired RSUs is dependent on the company's stock performance and the director's continued employment until the vesting date of May 18, 2027.

Industry Context

StockSavvy.ai notes that insider grants of equity, such as these RSUs, are common in the biotechnology sector as a means to attract and retain key talent and align executive interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The acquisition of RSUs by a director can be seen as a positive signal of commitment, potentially aligning director interests with shareholder value creation.
• Employees: The use of RSUs as compensation can be a standard practice, but the specific details of this grant do not directly impact other employees.
• Management: The director's compensation is directly affected by the vesting and future stock performance of these RSUs.

Next Steps

• The director will continue to provide services to Acrivon Therapeutics, Inc. until May 18, 2027, for the RSUs to vest.
• Upon vesting, the director will receive one share of Acrivon Therapeutics' Common Stock for each RSU.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, SEC Filing, Director, Restricted Stock Units, RSUs, Equity Award, Beneficial Ownership, Insider Trading